Epstein-Barr Virus Glycoprotein Antibody Titers and Risk of Nasopharyngeal Carcinoma

We evaluated antibody against Epstein-Barr virus glycoproteins (gp350, gH/gL, gB, gp42) in 97 nasopharyngeal carcinoma (NPC) cases and 97 cancer-free controls. Each unit increase in log-transformed antibody against gp350 and gH/gL was associated with 2.27 (95% confidence interval [CI], 1.20–4.29) an...

Descripción completa

Detalles Bibliográficos
Autores principales: Coghill, Anna E, McGuire, Andrew, Sinha, Sweta, Homad, Leah, Sinha, Irika, Sholukh, Anton, Koh, Woon-Puay, Yuan, Jian Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745775/
https://www.ncbi.nlm.nih.gov/pubmed/36519117
http://dx.doi.org/10.1093/ofid/ofac635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9745775/
https://www.ncbi.nlm.nih.gov/pubmed/36519117
http://dx.doi.org/10.1093/ofid/ofac635

Ejemplares similares